Topic
Topic
Pfizer reports its trispecific antibody achieved significant skin clearance in a Phase 2 atopic dermatitis trial, signaling a potential new biologic mechanism beyond the IL-4/IL-13 axis for moderate-…
Lutris Pharma presented updated Phase 2 data at EADV showing durable, mechanism-directed benefit of LUT014 topical gel for acneif…
AbbVie presented positive Phase 2 APEX Part B results for the IL-13 inhibitor zumilokibart in moderate to severe atopic dermatiti…
AbbVie reports zumilokibart met its primary endpoint in a phase 2 atopic dermatitis trial, advancing a key pipeline asset toward…
Zumilokibart improved moderate-to-severe atopic dermatitis in a Phase 2 trial and will advance to Phase 3, with detailed efficacy…
